Comment
Author: Admin | 2025-04-28
60 MG TICAGRELOR TWICE DAILY January 27, 2036✓ Patent use: REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarctionPatent 10300065*PEIssued: May 28, 2019Inventor(s): Andersson Lars Magnus & Andersson Tomas Lars-Gunnar & Bengtsson Olof Fredrik & Held Hans Peter & Howells Garnet Edward & Jensen Eva Christina & Storey RobertAssignee(s): ASTRAZENECA ABThe present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.Patent expiration dates: July 27, 2036 Pharmaceutical compositionsPatent 8,425,934Issued: April 23, 2013Inventor(s): Banks SimonAssignee(s): AstraZeneca ABThe present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1α,2α,3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.Patent expiration dates: April 17, 2030✓ Drug product Pharmaceutical compositionsPatent 8425934*PEDIssued: April 23, 2013Inventor(s): Banks SimonAssignee(s): AstraZeneca ABThe present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1α,2α,3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.Patent expiration dates: October 17, 2030✓ Pediatric exclusivity Triazolo(4,5-D)pyrimidine compoundsPatent RE46276Issued: January 17, 2017Inventor(s): Hardem David & Ingall Anthony & Springthorpe Brian & Willis Paul & Guile SimonAssignee(s): AstraZeneca UK LimitedTriazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows:Patent expiration dates: October 30, 2024✓ Patent use: REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION✓ Drug substance✓ Drug product October 30, 2024✓ Patent use: TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION✓ Drug substance✓ Drug product October 30, 2024✓ Patent use: TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION✓ Drug substance✓ Drug product October 30, 2024✓ Patent use: TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION✓ Drug
Add Comment